Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

计划入组 44 人 · 首次发布于 2025 年 10 月 9 日

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

计划入组 240 人 · 首次发布于 2025 年 10 月 10 日

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

计划入组 300 人 · 首次发布于 2023 年 12 月 8 日

Pegcetacoplan(Empaveli, Syfovre, Aspaveli)

Rx

Apellis Pharmaceuticals

United States

Apellis' Syfovre Approved in Australia for Geographic Atrophy

Apellis' Syfovre Rejected Again in Europe for Geographic Atrophy

EU Confirms Rejection of Apellis' Pegcetacoplan for Geographic Atrophy